The Firm’s investigation is centered on BELLUS’ statements concerning the efficacy of its lead drug candidate, BLU-5937, which is BELLUS’ only drug in a clinical trial. BLU-5937 is designed to treat refractory chronic cough, which impacts millions of patients.
On July 6, 2020, BELLUS announced the topline results for its Phase 2 RELIEF trial for BLU-5937. The drug was unable to outperform placebo.
On this news, shares of BELLUS common stock plummeted over 70%, closing at just $3.40 per share on July 6, 2020.
Investors who have lost money on their Bellus shares may be able to recover some of those losses and should contact us using the form below.